Protalix BioTherapeutics (PLX) Operating Leases (2019 - 2026)
Protalix BioTherapeutics' quarterly Operating Leases came in at $7.0 million in Q1 2026, up 84.94% year-on-year from $3.8 million in Q1 2025, and up 1.6% quarter-over-quarter from $6.9 million in Q4 2025.
Protalix BioTherapeutics has reported Operating Leases for 8 years, with the latest figure at $7.0 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Leases rose 84.94% year-over-year to $7.0 million; the trailing twelve-month figure through Mar 2026 stood at $7.0 million (up 84.94% YoY), and the FY2025 full-year result was $6.9 million, up 72.31% from the prior year.
- Operating Leases for Q1 2026 stood at $7.0 million, up from $6.9 million in the prior quarter.
- The five-year high for Operating Leases was $7.0 million in Q1 2026, with the low at $3.8 million in Q1 2025.
- Average Operating Leases over 5 years is $4.7 million, with a median of $4.2 million recorded in 2022.
- Year-over-year, Operating Leases decreased 15.29% in 2025 and jumped 84.94% in 2026.
- Tracing PLX's Operating Leases over 5 years: stood at $4.2 million in 2022, then gained by 10.84% to $4.6 million in 2023, then declined by 12.88% to $4.0 million in 2024, then soared by 72.31% to $6.9 million in 2025, then increased by 1.6% to $7.0 million in 2026.
- The last three Operating Leases figures came in at $7.0 million (Q1 2026), $6.9 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.05 Mn |
| Dec 31, 2025 | 6.94 Mn |
| Sep 30, 2025 | 6.78 Mn |
| Jun 30, 2025 | 3.88 Mn |
| Mar 31, 2025 | 3.81 Mn |
| Dec 31, 2024 | 4.03 Mn |
| Sep 30, 2024 | 4.18 Mn |
| Jun 30, 2024 | 4.28 Mn |
| Mar 31, 2024 | 4.50 Mn |
| Dec 31, 2023 | 4.62 Mn |
| Sep 30, 2023 | 4.50 Mn |
| Jun 30, 2023 | 4.58 Mn |
| Mar 31, 2023 | 4.15 Mn |
| Dec 31, 2022 | 4.17 Mn |
| Sep 30, 2022 | 4.03 Mn |
| Jun 30, 2022 | 3.89 Mn |
| Mar 31, 2022 | 4.19 Mn |
| Dec 31, 2021 | 4.38 Mn |
| Sep 30, 2021 | 4.44 Mn |
| Jun 30, 2021 | 4.51 Mn |
| Mar 31, 2021 | 4.32 Mn |
| Dec 31, 2020 | 4.47 Mn |
| Sep 30, 2020 | 4.56 Mn |
| Jun 30, 2020 | 4.53 Mn |
| Mar 31, 2020 | 4.48 Mn |
| Dec 31, 2019 | 5.70 Mn |
| Sep 30, 2019 | 4.53 Mn |
| Jun 30, 2019 | 4.57 Mn |
| Mar 31, 2019 | 5.76 Mn |